eli lilly gip/glp-1 title Lilly's investigational weight-loss drug has cleared a pivotal Phase 3 trial, delivering weight loss of up to 30 percent. The results add to growing interest in the next wave of Lilly's triple-acting obesity drug hits

Di Stefano G, Di Lionardo A, Galosi E, et al

Thank you all Yours truly Ruth

Neurological injuries

27 Feb, 2026 We want to hear from you Everything you need to know

Common side effects include: Nausea and an unsettled stomach, particularly in the early weeks of treatment Vomiting in some cases, especially when doses are increased Digestive changes including constipation or diarrhea Reduced appetite, which is partly how these medications support weight loss Rare but serious side effects include: Pancreatitis: inflammation of the pancreas, which requires immediate medical attention Gallbladder complications such as gallstones or cholecystitis A theoretical risk of medullary thyroid carcinoma has been observed in animal studies, though this has not been confirmed in human clinical data Most common side effects are temporary and tend to ease as your body adjusts to the medication